title: Computer aided screening of Accacia nilotica phytochemicals against HCV NS3/4a.
abstract: BACKGROUND
  HCV has become a leading cause of liver cirrhosis and hepatocellular carcinoma and is a major health concern worldwide. To date, there is no vaccine available in the market to tackle this disease, therefore there is a strong need to develop antiviral compounds that can target all genotypes of HCV with the same efficiency. Medicinal plants have low cost and are less toxic therefore, extracts of medicinal plants can serve as important antiviral agents against HCV. This study was designed to screen phytochemicals of Accacia nilotica to find a potent drug candidate that can inhibit HCV infection effectively.
  
  
  RESULTS
  Docking of NS3/4A protease and Flavonoids of Accacia nilotica revealed that most of the flavonoids bound deeply with the active site of NS3/4A protease. Compound 01 showed a high ranking on docking score. All other compounds also showed reliable docking scores and had interactions with the binding cavity of NS3/4A protease, suggesting them as a potent drug candidate to block HCV replication.
  
  
  CONCLUSIONS
  To recognize binding interactions of Accacia nilotica phytochemicals with NS3/4A protease, molecular docking was performed to find potential inhibitor against NS3/4A protease of HCV. After post docking analysis, important interactions were found between active compounds and active site of NS3/4A protease. It can be concluded from the study that phytochemicals of Accacia nilotica may serve as a potential drug candidate with relatively simple structural changes against HCV NS3/4A protease.
authors: Department of Bioinformatics and Biotechnology, Government College University (GCU), Faisalabad, Pakistan.
authors: Mahim
authors: M
authors: Khan
authors: Muhammad
authors: M
authors: Qasim
authors: Usman Ali
authors: UA
authors: Ashfaq
authors: Sobia
authors: S
authors: Idrees
authors: Masoud
authors: M
authors: Shah
references: Nature. 2005 Aug 18;436(7053):967-72
references: 16107837
references: Virol J. 2011 Apr 11;8:161
references: 21477382
references: Plant Physiol. 2000 Oct;124(2):507-14
references: 11027701
references: J Appl Microbiol. 2003;95(3):412-27
references: 12911688
references: J Virol. 1994 Aug;68(8):5045-55
references: 8035505
references: Recent Pat Antiinfect Drug Discov. 2008 Nov;3(3):157-67
references: 18991798
references: Mini Rev Med Chem. 2008 Jun;8(7):657-68
references: 18537721
references: J Ethnopharmacol. 1991 Apr;32(1-3):141-53
references: 1652667
references: Clin Microbiol Rev. 1999 Oct;12(4):564-82
references: 10515903
references: Altern Med Rev. 2001 Dec;6(6):567-79
references: 11804547
references: Hepatology. 2003 Jul;38(1):75-85
references: 12829989
references: Virol J. 2011 May 12;8:220
references: 21569385
references: Hepatology. 2011 Oct;54(4):1433-44
references: 21898493
references: J Virol. 2010 Nov;84(21):10991-8
references: 20810735
references: Top Antivir Med. 2012 Dec;20(5):154-61
references: 23363693
references: Genet Vaccines Ther. 2011 Apr 06;9:7
references: 21466709